2012 Friends-Brookings Conference on Clinical Cancer Research

Each year, Friends of Cancer Research (Friends) and the Engelberg Center for Health Care Reform at Brookings convene the Conference on Clinical Cancer Research to address critical issues in the development of new drugs. This annual conference brings together leaders from federal health and regulatory agencies, academic research centers, patient advocacy organizations and the private sector to propose consensus solutions and develop a clear path forward on critical issues surrounding the development and regulation of drugs and therapies.

On November 14, 2012, the fifth-annual Conference on Clinical Cancer Research was convened in Washington DC with the support of Susan G. Komen for the Cure, the American Society of Clinical Oncology (ASCO), and the American Association for Cancer Research (AACR). The 2012 conference focused on new policies and research strategies to improve and expedite drug development. Through a series of Issue Briefs released at the meeting, members of the expert panels proposed ways to implement the newly created Breakthrough Therapies designation and how to optimize the Accelerated Approval pathway. In addition, a proposal for a biomarker-driven, multi-drug registration trial for potential agents to treat lung cancer was also presented as an innovative approach to accelerate drug development.

For more information on the 2012 Friends-Brookings Conference on Clinical Cancer Research, click HERE.